National regulators throughout the EU will ask manufacturers of rifampicin-containing medicines to check their products for nitrosamine impurities before they are released for sale.
Regulators in the EU have introduced new testing requirements for all medicines containing the antibiotic drug, rifampicin, to address concerns that they may be contaminated with cancer-causing nitrosamine impurities.
Rifampicin is a first-line treatment for tuberculosis and is also used for treating several other serious infections, including blood infections...
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
